Skip to main content
Signal8

Fresenius SE & Co. KGaA (FSNUY)

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Care Facilities

Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA

OTC:FSNUYHealthcare
-2.72%$14.28
Mkt Cap$128.69B
EV-
Float1.64B
O/S9.01B
VOL131K sh
$ Vol$1.88M
RVOL1.37×
Inst Own-
SI<0.1%
Net Cash/Sh-
Div Yield2.13%
Dilution
Fresenius SE & Co. KGaA logoOTC:FSNUY$14.28-2.72%
Short interest (FINRA)
0.0%
Oct 30 (21d)

Float 1.64B · Market-data free float

53.8K
Oct 30 (21d)prev 367.3K▼ 85.3%
1.00
Oct 30 (21d)prev 1.00– 0.0%
Borrow

The cost to borrow FSNUY shares for a short sale and how many shares are available to borrow, refreshed through the session.

Borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
79.4%
Nov 19 (1d)prev 58.0%▲ 21.4 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

258.7K
Oct 19 (32d)prev 467.2K▼ 44.6%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202653.8K sh
Oct 15, 2026367.3K sh
Sep 30, 202628.9K sh
Sep 15, 202659.9K sh
Aug 31, 202632.1K sh
Latest fails to deliver
DateShares failed
Oct 19, 2026258.7K sh
Oct 16, 2026467.2K sh
Oct 15, 2026216.4K sh
Oct 9, 202610 sh
Oct 7, 2026386.7K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 19
Latest sessions
DateReported short
Nov 19, 202679.4%
Nov 18, 202658.0%
Nov 17, 202654.9%
Nov 16, 202654.0%
Nov 13, 202666.1%
92-session median 45.7%mean 48.2%range 8.3–89.7%

130 calendar days requested; 93 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for FSNUY: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 53,811 FSNUY shares were sold short (<0.01% of a 1.64B-share float, 1.00 days to cover).